Status | Study |
Recruiting |
Study Name: Tissue Microarrays (TMAs) Construction in Lung Cancer Samples Condition: Lung Cancer Date: 2017-04-21 |
Not yet recruiting |
Study Name: Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Condition: Microsatellite Stable Colorectal Cancer Pancreatic Cancer Date: 2017-04-03 Interventions: Drug: Nivolumab The antibodies |
Recruiting |
Study Name: Does Sevoflurane Cause Genomic Damage Condition: Anesthesia; Adverse Effect Date: 2017-03-20 Interventions: Drug: Sevoflurane The patients |
Not yet recruiting |
Study Name: Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Condition: Carcinoma, Renal Cell Head and Neck Neoplasm Skin Neoplasm Date: 2017-01-02 Interventions: Drug: Nivolumab Treatment Other Name: Opdivo |
Active, not recruiting |
Study Name: Safety of Ginkgo Biloba Leaf Extract Condition: Healthy Date: 2016-12-20 Interventions: Dietary Supplement: Gingko Biloba Extract |
Not yet recruiting |
Study Name: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer Condition: Colorectal Adenocarcinoma High-Frequency Microsatellite Instability Date: 2016-12-19 Interventions: Drug: Atezolizumab Given IV |
Not yet recruiting |
Study Name: Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Condition: Castration Levels of Testosterone Hormone-Resistant Prostate Cancer Date: 2016-11-15 Interventions: Biological: Durvalumab Given I |
Not yet recruiting |
Study Name: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability Condition: Colon Adenocarcinoma DNA Repair Disorder Lynch Syndrome Date: 2016-09-22 Interventions: Drug: Atezolizumab Given IV |
Recruiting |
Study Name: A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer Condition: MSI-L/MSS Stage II Colon Cancer Date: 2016-08-01 Interventions: Drug: tegafur-uracil |
Recruiting |
Study Name: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors Condition: Solid Tumor Microsatellite Instability-High (MSI-H) Solid Tumors Date: 2016-06-01 Interventions: Drug: LY3300054 Administered I |